Boduła Andrzej, Wdowczyk Michał, Adamiec Rajmund
Klinika Angiologii, Nadciśnienia Tetniczego i Diabetologii Akademii Medycznej, Wrocław.
Postepy Hig Med Dosw (Online). 2005 May 16;59:203-7.
Insulin resistance plays an important role in the development of such abnormalities as impaired glucose tolerance, type 2 diabetes, obesity, and hyperlipidemia. The rates of these diseases are increasing and their cardiovascular complications are among the most common causes of death worldwide. The discovery of protein tyrosine phosphatase (PTP-1B) seems to be a milestone in the investigation of insulin signaling transmission. PTP-1B is considered a negative regulator of insulin signaling, mainly through insulin receptor dephosphorylation. In animal model studies (Elchebly et al.) there was a significant increase in insulin sensitivity of PTP-1B knock-out mice. There is also evidence that higher expression of the PTP-1B gene causes insulin resistance in humans. PTP-1B inhibitors could thus be promising drugs for insulin resistance therapy. The object of this review is to present current evidence of PTP-1B's role in the pathophysiology of insulin resistance abnormalities and the potential treatment of these disorders.
胰岛素抵抗在诸如糖耐量受损、2型糖尿病、肥胖症和高脂血症等异常病症的发展过程中起着重要作用。这些疾病的发病率正在上升,且其心血管并发症是全球范围内最常见的死亡原因之一。蛋白酪氨酸磷酸酶(PTP - 1B)的发现似乎是胰岛素信号传导研究中的一个里程碑。PTP - 1B被认为是胰岛素信号的负调节因子,主要通过使胰岛素受体去磷酸化来实现。在动物模型研究中(埃尔切布利等人),PTP - 1B基因敲除小鼠的胰岛素敏感性显著增加。也有证据表明,PTP - 1B基因的高表达会导致人类出现胰岛素抵抗。因此,PTP - 1B抑制剂可能是治疗胰岛素抵抗的有前景的药物。本综述的目的是展示关于PTP - 1B在胰岛素抵抗异常病理生理学中的作用以及这些病症潜在治疗方法的当前证据。